Meeting
2019 Supportive Care in Oncology Symposium
Eflapegrastim, a novel, long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.
Authors
Lee S. Schwartzberg
West Cancer Center, Germantown, TN
Lee S. Schwartzberg, Gajanan Bhat, Jayaram S. Bharadwaj, Osama Hlalah, Alvaro Restrepo, Inderjit Mehmi, Shanta Chawla, Patrick Wayne Cobb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Advance Care Planning,End-of-Life Care,Communication and Shared Decision Making,Integration and Delivery of Palliative and Supportive Care,Coordination and Continuity of Care,Caregiver Support,Biology of Symptoms and Treatment Toxicities,Disparities in Supportive Care
Sub Track
Integration and Delivery of Palliative and Supportive Care
Clinical Trial Registration Number
NCT02643420 and NCT02953340
Citation
J Clin Oncol 37, 2019 (suppl 31; abstr 61)
DOI
10.1200/JCO.2019.37.31_suppl.61
Abstract #
61
Poster Bd #
F4
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.
First Author: Lee S. Schwartzberg
Poster
2020 ASCO Virtual Scientific Program
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).
First Author: Volker Moebus
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw
Poster
2021 ASCO Annual Meeting
Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.
First Author: Douglas W. Blayney